MEDICATION USE AND FALLS IN OLDER ADULTS: 

A PHARMACOEPIDEMIOLOGIC APPROACH by Marcum, Zachary et al.
 MEDICATION USE AND FALLS IN OLDER ADULTS:  
A PHARMACOEPIDEMIOLOGIC APPROACH 
 
 
 
 
 
 
 
 
by 
Zachary Adam Marcum 
Pharm.D., Butler University, 2008 
M.S., University of Pittsburgh, 2011 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy in Clinical and Translational Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2014 
 
 ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Zachary Adam Marcum 
 
 
 
It was defended on 
September 26, 2014 
and approved by 
Nicholas Castle, M.H.A., Ph.D., Professor, University of Pittsburgh Graduate School of Public Health 
Joseph Hanlon, Pharm.D., M.S., Professor, University of Pittsburgh School of Medicine 
Subashan Perera, PhD., Associate Professor, University of Pittsburgh School of Medicine 
Joshua Thorpe, Ph.D., M.P.H., Associate Professor, University of Pittsburgh School of Pharmacy 
Dissertation Advisor: Galen E. Switzer, Ph.D., Professor, University of Pittsburgh School of Medicine 
 
 
 iii 
Copyright © by Zachary Adam Marcum 
2014 
 iv 
 
More than one-third of community-dwelling older adults fall each year. Falling is 
classified as a geriatric syndrome which has multiple contributing factors and an interaction 
between chronic predisposing diseases and impairments and acute precipitating insults. One 
potentially modifiable risk factor is medication use. While previous research has been conducted 
on medication-related falls, there are several gaps remaining in the literature, including the lack 
evidence on dose-response relationships across wide ranges of medication classes and falls as 
well as the frequent inability to address confounding by indication. Therefore, the overall 
purpose of this project was to determine—in a large, representative sample of community-
dwelling older adults—associations between antihypertensive, anticholinergic, and 
antidepressant use and recurrent falls.  
First, we found no increased risk of recurrent falls in antihypertensive users compared to 
non-users, or those taking higher doses or for longer durations. Only those using a loop diuretic 
were found to have a modest increased risk of recurrent falls. In conclusion, antihypertensive use 
overall was not associated with recurrent falls after adjusting for important confounders. Loop 
diuretic use may be associated with recurrent falls and needs further study. 
Second, we found no statistically significant increased risk of recurrent falls in 
anticholinergic users, or those taking higher doses or for longer durations. In conclusion, 
increased point estimates suggest an association of anticholinergic use with recurrent falls, but 
MEDICATION USE AND FALLS IN OLDER ADULTS:  
A PHARMACOEPIDEMIOLOGIC APPROACH 
  
Zachary Adam Marcum, Pharm.D., M.S. 
University of Pittsburgh, 2014
 
 v 
the associations did not reach statistical significance. Future studies are needed to examine other 
measures of anticholinergic burden, and their associations with other outcomes such as cognitive 
function. 
Third, we found a statistically significant increased risk of recurrent falls in 
antidepressant users. An increased risk was also seen among those taking SSRIs, those with short 
duration of use, and those taking moderate doses. Among those with a history of falls/fracture at 
baseline, we found an increase in risk for any antidepressant use, but no increased risk was found 
in those without a history of falls/fracture. 
Taken together, the findings from this proposal will provide clinicians and researchers 
with clinically-relevant information on potential harmful outcomes associated with chronic 
medication therapy among older adults. 
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1.0  INTRODUCTION 
Pharmacoepidemiology is the study of the use of and the effects of drugs in large numbers of 
people.
1
 The potential contributions of pharmacoepidemiology include:                 (1) 
supplemental information to premarketing studies and better quantifying the incidence of known 
adverse and beneficial effects in certain populations not studied prior to marketing (e.g., elderly, 
children, or pregnant women); (2) new types of information not available from premarketing 
studies (e.g., undetected adverse and beneficial effects, patterns of utilization); and (3) 
reassurances about drug safety and fulfillment of ethical and legal obligations.
1
 Overall, 
questions that pharmacoepidemiologic studies can answer include: (1) What are the beneficial 
and harmful outcomes of drug therapy?; (2) What interventions are effective in modifying the 
use and outcomes of drug therapy?; and (3) How and why is drug therapy being used/misused or 
prescribed?
1
  
Moreover, medications are the most frequently used form of therapy for the medical 
problems of the aged.
2
 Unfortunately, the frequent exclusion of this age group from 
premarketing clinical trials of new medications has limited our knowledge regarding the safety 
and efficacy and individual medications in this population.
2
 Further, older patients often have 
various chronic conditions that may require long-term medications. Of potential concern is that 
multiple medication use (polypharmacy) can lead to problems in the medication use process and 
related health outcomes. Thus, pharmacoepidemiologic studies are critically important to 
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understand and improve the use of medications in older adults. One of the most important 
medication-related problems in older adults is falling.  
More than one-third of community-dwelling older adults fall each year.
3
 Approximately 
10% of falls result in a major injury such as a fracture, serious soft tissue injury, or traumatic 
brain injury.
3
 In addition, falls are major contributors to functional decline and health care 
utilization. Falls and fall injuries are among the most common causes of decline in the ability to 
care for oneself and to participate in social and physical activities. As with other conditions 
affecting older adults, falling is classified as a geriatric syndrome which has multiple 
contributing factors and an interaction between chronic predisposing diseases and impairments 
and acute precipitating insults.
3
 One potentially modifiable risk factor is medication use.
4
 While 
previous research has been conducted on medication-related falls, there are several gaps 
remaining in the literature, including the lack evidence on dose-response relationships across 
wide ranges of medication classes and falls as well as the frequent inability to address 
confounding by indication. 
Using an existing data source available at the University of Pittsburgh, this proposal was 
an in-depth analysis of the first type of question answerable through a pharmacoepidemiologic 
approach (i.e., the harmful outcomes of drug therapy) which evaluated the association between 
three different medication classes and falls among community-dwelling older adults. All three 
analyses utilized data from the Health, Aging and Body Composition (Health ABC) Study. The 
proposed longitudinal analyses used data collected from 3,075 black and white men and women 
aged 70-79 enrolled in 1997/98 into the Health ABC Study and followed them from year 1 
(baseline) to the year 7 follow-up.
5
 Sample members representative of elders in Pittsburgh and 
Memphis initially reported no difficulty walking at least ¼ mile or up a flight of stairs. The 
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information sought over the seven year period included a battery of detailed physiologic and 
performance measurements and questionnaire material regarding sociodemographic 
characteristics, multiple aspects of the participants' physical health, and use of medications (at 
certain years). For medications, at baseline, years 2, 3, 5, and 6 participants were asked to bring 
to clinic all medications they had taken in the previous two weeks. In clinic, the interviewer 
gathered up all prescription and non-prescription drugs and transcribed from the medication 
container information about the drug name, strength, dosage form, prescription or non-
prescription status, whether the drug was taken ―prn‖ or as needed, the number of times the 
respondent reported taking the product the previous day, week, or month, and when they started 
the drug. The medication data collected for the Health ABC Study was edited, coded using the 
Iowa Drug Information System (IDIS) ingredient codes and entered into a computerized 
database.
6 
It is important to note that Health ABC is an ideal data source for conducting the 
proposed analyses. Previous studies assessing the association between medications and falls in 
older adults have been limited by their inability to control for the underlying indication for drug 
use, which Health ABC data will be able to address. In addition, prior research has been limited 
in terms of the medication data available such that they were frequently not able to look at the 
impact of dosage or duration of pharmacotherapy on the outcome of falls.
7
 The proposed 
analyses were able to calculate robust medication variables including dosage and duration. 
Finally, a major strength of the Health ABC dataset is its inclusion of both prescription and over-
the-counter medication information. Most medication datasets do not include over-the-counter 
medication data.  
 4 
In conclusion, the overall purpose of this project was to determine—in a large, 
representative sample of community-dwelling older adults—associations between 
antihypertensive, anticholinergic, and antidepressant use and recurrent falls. The findings from 
this proposal provide clinicians and researchers with clinically-relevant information on potential 
harmful outcomes associated with chronic medication therapy among older adults. 
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2.0  ANTIHYPERTENSIVE USE AND RECURRENT FALLS IN COMMUNITY-
DWELLING OLDER ADULTS: FINDINGS FROM THE HEALTH ABC STUDY 
2.1 INTRODUCTION 
Hypertension (especially systolic) is the most common chronic condition in older adults.
8
 If un- 
or undertreated, hypertension can increase risk of stroke, heart failure and premature death.
8
 
Numerous randomized controlled trials demonstrate the effectiveness of thiazide diuretics, 
central alpha blockers, renin-angiotensin-aldosterone system inhibitors, and calcium channel 
blockers in reducing blood pressure in adults well into their eighties.
8
 Even though these drugs 
are generally well tolerated, as few as 50% of elders with hypertension use antihypertensives, 
and fewer than 50% of these have adequate blood pressure control.
9
 
Suboptimal blood pressure control may derive, in part, from concerns about adverse drug 
effects, including falls. Indeed, 18-40% of community-dwelling elderly fall yearly
10-12
, of whom 
nearly 50% have recurrent falls.
12,13
 Recurrent falls (as opposed to single falls) may be more 
clinically important since they can be a marker of physical and cognitive status problems, and 
other morbidity and mortality in the elderly.
12
 A previous meta-analysis and a cohort study found 
antihypertensive use modestly increased risk of a single fall
14,15
; whether antihypertensive use is 
associated with recurrent falls and whether this risk varies by medication class, dose response, 
and duration response associations over time is relatively unknown. 
 6 
Thus, the objective of the current longitudinal study was to assess the association of overall and 
specific classes of antihypertensive use, dose, and duration with recurrent falls in community-
dwelling, initially well-functioning elders. 
 7 
 
2.2 METHODS 
2.2.1 Study design, data source, and sample 
We used data from the Health, Aging, and Body Composition (Health ABC) study, a population-
based, prospective, longitudinal observational study of community-dwelling older adults.
5
 This 
study was approved by the University of California at San Francisco (UCSF), University of 
Pittsburgh, and University of Tennessee Memphis Institutional Review Boards, and informed 
consent was obtained from each participant prior to data collection. The baseline sample 
(1997/98) included 3,075 Black and White men and women aged 70-79 years who reported no 
difficulty walking ¼ mile, or climbing 10 steps and lived in specified zip codes surrounding 
Pittsburgh, PA and Memphis, TN.
5
 The sample for the current analysis included 2,948 older 
adults at year 1 with complete medication use and fall data the following year followed through 
year 6 for antihypertensive medication exposure and year 7 for recurrent falls. 
2.2.2 Data collection and management 
Participants were seen annually during a clinic or home visit and detailed physiologic (including 
blood pressure) and self-report questionnaire measurements (including demographics, health 
behavior/status (including medications), and access to health care factors were collected.
5
 
Detailed medication data were collected in clinic or at home about products taken in the previous 
 8 
month using a state of the art ―brown bag‖ review method.16,17 A similar data collection approach 
was used for telephone interviews if participants were unable to be seen in person. Studies have 
shown that medication use information collected by either ―brown bag‖ or telephone methods are 
highly accurate and concordant with information about dispensed prescription drugs in claims 
data.
18,19
 For all medications, the interviewer recorded the name, strength, dosage form, and the 
number of dosage forms the respondents said they had used the previous day, week, or month. 
The medication data collected for the Health ABC Study were edited and coded using the Iowa 
Drug Information System (IDIS) Drug Vocabulary and Thesaurus.
6
 IDIS is a hierarchical coding 
system with 8 character unique codes for specific drug ingredients, chemical and therapeutic 
categories. The therapeutic category code allows drugs to be assigned to one of 20 major 
therapeutic classes and 200 sub-classes based on an expanded version of the American Hospital 
Formulary Services format.
20
 
Teleform was used to create scannable forms for direct data entry. Missing and 
questionable values were highlighted by the software for visual review and online editing. 
Additional range checks and data cleaning were conducted at the UCSF Coordinating Center. 
De-identified SAS
®
 permanent data files were created for analysis. 
2.2.3 Primary outcome 
The number of falls in which the participant landed on the floor or ground in the previous twelve 
months was assessed at the year following medication use data collection (e.g., year 1 
antihypertensive use and previous year falls reported at year 2) for each wave (five waves). The 
primary outcome was recurrent falls (≥ two) in the ensuing 12 months following report of 
medication use. This method of fall recall (in the previous 12 months) has been shown to be 
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highly specific (91% – 95%) in comparison with that reported using more frequent 
assessments.
21
 
2.2.4 Primary independent variable 
Medications used to treat hypertension were grouped into therapeutic sub-classes: 1) beta 
blockers (IDIS codes:12160107, 12160114, 12160115, 12160123, 12160137, 12160145, 
12160146, 12160150, 12160153, 12160167, 12160169); 2) alpha blockers (peripheral and 
central) (IDIS codes: 12160401, 12160404, 12160419, 24080006, 24080010, 24080063, 
24080064, 24080084); 3) loop diuretics (IDIS codes: 40280401, 40280402, 40280405); 4) 
thiazide diuretics (IDIS codes: 40280025, 40280101, 40280106, 40280108, 40280110); 5) 
potassium-sparing diuretics (IDIS codes: 40280013, 40280016, 40280062); 6) calcium channel 
blockers (IDIS codes: 24120406, 24120410, 24120413, 24120415, 24120416, 24120421, 
24120422, 24120449); 7) angiotensin converting enzyme inhibitors (ACEI) (IDIS codes: 
24080202, 24080203, 24080206, 24080208, 24080213, 24080214, 24080216, 24080218, 
24080223, 24080232); and 8) angiotensin receptor blockers (ARBs) (IDIS codes: 24080401, 
24080402, 24080403, 24080405, 24080410, 24080412).
22
 Too few participants were taking 
vasodilators so this class was not assessed. Any use was defined as the use of any medication 
from the 8 sub-classes. To evaluate the possibility of a dose-response relationship, the daily dose 
was calculated for current users for each individual antihypertensive medication by multiplying 
the number of dosage forms taken the previous day by the strength of the medication reported at 
the interview. The daily dose was then converted to a standardized daily dose (SDD) by dividing 
it by the maximum effective dose per day as noted in a standard reference.
22
 Thus, a person 
taking 1.0 standardized antihypertensive drug unit would have taken the maximum 
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recommended effective daily dose for one agent. The standardized dose was summated for all 
antihypertensives, regardless of class, taken daily. Finally, to examine the impact of duration, 
long-term use was operationally defined as ≥ 2 years and short-term use as < 2 years. 
2.2.5 Control variables 
To address potential confounding, we controlled for a number of demographic, health 
status/behavior, and access to care factors.
12,13
 Demographic factors included age, sex, race, site, 
education (less than a high school education, high school graduate, and post-secondary 
education), and marital status (never married, married, previously married). 
Health behaviors included smoking status and alcohol use. Health status factors included 
pulmonary disease, arthritis, urinary problems, cerebrovascular disease, bodily pain in the 
previous month, vision (excellent/good sight, fair sight, and poor to completely blind), and body 
mass index (underweight/normal, <24.9; overweight, 25.0-29.9; and obese, ≥30).17,22 Self-rated 
global health was dichotomized as excellent/very good/good vs. fair/poor. In addition, time-
varying covariates were created for depressive symptoms (Short Center for Epidemiologic 
Studies-Depression Scale >10), cognitive impairment (Modified Mini-Mental State Test [3MS] 
<80), exposure to any drug that increases the risk of falls (non-anticholinergic central nervous 
system medications, including benzodiazepines, antidepressants, antipsychotics, opioids), and 
the total number of prescription medications (excluding dugs that increase falls, and 
antihypertensive drugs) per participant.
13,23,24
 Access to care factors included dichotomous 
variables for hospitalization in previous 12 months, private physician, prescription insurance, and 
flu shot in previous 12 months.
25
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Self-reported hypertension was sub-divided into controlled (>140/90 mmHg) and 
uncontrolled on a time-varying basis. Antihypertensives can be used for a number of comorbid 
conditions.
8,25
 Therefore, to mitigate potential confounding by indication, we included self-
reported peripheral artery disease, benign prostatic hyperplasia symptoms, coronary heart 
disease, congestive heart disease, and diabetes.  
2.2.6 Statistical Analysis 
We used appropriate descriptive statistics for summarization and generalized estimating 
equations (GEE) for eliciting the main findings.
26-28
 First, we assessed the unadjusted association 
between antihypertensive use and recurrent falls over time. Second, a priori covariates that may 
affect recurrent falls were included: site, heart failure, benign prostatic hypertrophy, cognitive 
impairment, depressive symptoms, self-reported hypertension (controlled/uncontrolled), and 
other drugs that increase the risk of falls. Each antihypertensive sub-class was run as a separate 
model and controlled for antihypertensive sub-class use other than the sub-class being evaluated. 
Finally, additional covariates were selected using a forward stepwise selection approach applied 
separately for each of three domains of covariates (demographic, health status/behavior, and 
access to health care). Specifically, stepwise detected covariates and those deemed important a 
priori were included in the final model. We also conducted sensitivity analyses by restricting the 
sample to only those with hypertension (whether controlled or uncontrolled) at baseline, and 
stratifying the analysis by any falls history at baseline.  
To address potential confounding, and make the comparisons between those with and 
without antihypertensive use as balanced as possible within the framework of existing data from 
an observational study, we created propensity scores for the baseline time point and used two 
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approaches. First, we used all demographic, health status/behavior, and access to health care 
variables to create propensity scores using backward selection; propensity scores were then used 
in regression (covariance) adjustment.
29
 Specifically, we fit the primary model with any 
antihypertensive use as the independent variable and recurrent falls (yes/no) as the dependent 
variable, adjusting for propensity scores. Second, we stratified participants into quintiles based 
on the calculated propensity scores. Research has shown that stratification of propensity score 
balances all covariates that are used to estimate the propensity score, and often five sub-classes 
based on the propensity score will remove 90% of the bias in each of these covariates.
30
 The 
primary analysis (i.e., any antihypertensive use) was performed within each of the five strata to 
compare odds ratios and 95% confidence intervals for recurrent falls for those who received an 
antihypertensive versus those who did not. All analyses were conducted using SAS
®
 software 
(version 9.3; SAS Institute, Cary, NC). 
 13 
 
 
2.3 RESULTS 
At baseline, the mean (standard deviation) age was 73.6 (2.9) years, 51.6% were female, and 
40.8% were black (Table 1). In addition, slightly more than half had self-reported hypertension, 
and nearly half of those with hypertension were uncontrolled. 
Table 2 shows the prevalence of antihypertensive use over time. At baseline, over half 
reported the use of one or more antihypertensives, with calcium channel blockers being the most 
common class used (23%). At baseline, the overwhelming majority reported taking an 
antihypertensive for more than 2 years and in doses ≤ 2 SDDs. By year 6, 70% took one or more 
antihypertensives, with calcium channel blockers persisting as the most common class used 
(25.6%).  
At baseline, 21.2% of participants reported any fall in the previous year. At year 2, 8% of 
participants reported having recurrent falls in the previous year. This rate remained somewhat 
stable over the next four waves (7.5 to 10.4%).  
Table 3 shows the results from the multivariable model, controlling for demographic, 
health behavior/status, and access to care factors. We found no statistically significant increase in 
risk of recurrent falls in older antihypertensive users (adjusted OR 1.13, 95% CI 0.88-1.46), or 
those taking higher SDDs or for longer durations.   
Of the eight sub-classes, only loop diuretics were found associated with recurrent falls 
(adjusted OR 1.50, 95% CI 1.11-2.03). Post hoc analyses revealed no significant dose-response 
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relationship among loop diuretic users (SDD ≥1 adjusted OR 1.53, 95% CI 0.88-2.65; SDD <1 
adjusted OR 1.53, 95%CI 1.08-2.15). However, those taking a loop diuretic for ≥2 years had a 
significant increase in risk, but not for a shorter period of time (adjusted OR 1.64, 95%CI 1.10-
2.45 and adjusted OR 1.38, 95% CI 0.94-2.03, respectively).  
Multiple sensitivity analyses were conducted. Sensitivity analyses showed similar results 
when restricted to those with hypertension and when stratified by blood pressure control, and 
when stratified by those with a previous falls history at baseline (Tables 4 and 5). In addition, 
using the propensity scores in a covariance-adjusted model for the primary independent variable 
(i.e., any antihypertensive use) led to a similar overall finding (adjusted OR 1.07, 95% CI 0.81-
1.41). Stratification of the propensity scores into quintiles also led to similar findings (quintile 1: 
adjusted OR 0.89, 95% CI 0.31-2.52; quintile 2: adjusted OR 1.56, 95% CI 0.74-3.30; quintile 3: 
adjusted OR 0.87, 95% CI 0.49-1.55; quintile 4: adjusted OR 0.79, 95% CI 0.45-1.38; quintile 5: 
adjusted OR 1.31, 95% CI 0.78-2.21). 
 15 
 
 
2.4 DISCUSSION 
This study assessed the association between antihypertensive use and recurrent falls in 
community-dwelling older adults. We found a non-significant 13% increase in risk of recurrent 
falls with any antihypertensive use, which is lower than the 24% increased risk of a single fall 
associated with any antihypertensive use reported in the meta-analysis by Woolcott et al.
14
 
Moreover, our main finding is also lower than the point estimates detected by Tinetti et al 
(Hazard Ratios, 1.28-1.40).
15
 It is important to note our findings are robust in that our sensitivity 
analysis designed to address potential confounding by indication by restricting the sample to 
only those with hypertension (including whether or not it was controlled) found similar results. 
Unlike the study by Tinetti et al
15
, we did not find an increased risk among those with a history 
of falls at baseline.  
This study also explored both dose and duration response relationships with any 
antihypertensive use and recurrent falls and found no increased risk. This observation is 
consistent with Tinetti et al, who also failed to find a significant increase in risk of injurious falls 
in those in the high-intensity antihypertensive dose group (adjusted HR 1.28, 95% CI 0.91-
1.80).
15
 Neither did we find an increase in risk with respect to duration.  
In examining whether recurrent falls risk was elevated with use of any of 8 
antihypertensive sub-classes, we found a statistically significant 54% increase in risk of recurrent 
falls associated with loop diuretic use, but not with the remaining seven. A small, case-control 
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study similarly found over a two-fold increase in risk of falling in loop diuretic users versus the 
comparison group (31.1% versus 13.3%; p<0.05).
31
 A nursing home study using a novel case-
crossover design reported that nine persons with a loop diuretic change had a nearly 2.5 fold 
increased risk of a fall.
32
 Few other studies have found this relationship, however. A prospective 
cohort study of women found no association between loop diuretic use and recurrent falls
33
, and 
Tinetti’s analysis of both men and women did not uncover this specific risk.15 One explanation 
for the different findings may relate to duration of use, which we found to be an important factor. 
Further study is needed on the risk of falls with long-term loop diuretic use. One plausible 
explanation for this potential association is that loop diuretics can cause dehydration and/or 
hypotension, potentially causing dizziness and leading to a fall.  
There are important potential limitations to our study. First, the main outcome of 
recurrent falls was retrospectively collected via self-report. However, it is a highly specific 
method in comparison to self-reporting of falls via diary.
21
 Second, medication data were 
collected at fixed annual assessments, preventing us from documenting the exact date in which 
antihypertensive medications were initiated, changed, or discontinued. Third, while it is possible 
that there is residual confounding, we were mindful of potential confounding bias and adjusted 
for common indications for antihypertensive therapy. Moreover, our sensitivity analyses showed 
similar results when restricted to only those with hypertension and when stratified by those with 
a baseline falls history. Finally, our analysis focused on older, well-functioning community-
dwelling Black and White men and women from the Memphis and Pittsburgh areas, and the 
generalizability to older adults in other regions or different care settings is unknown. 
In conclusion, antihypertensive use overall was not associated with recurrent falls after 
adjusting for important confounders. Analyzed separately, however, loop diuretics were 
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significantly associated with recurrent falls. Future research is needed with larger sample sizes in 
both community and long-term care facility settings with older adults to improve the evidence 
base on about medication-related fall risk. 
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Table 1. Characteristics of the Sample at Baseline - Antihypertensives (n=2948) 
Variables Mean + SD or N, % 
Demographics  
Female gender 1522 (51.6) 
Black race 1203 (40.8) 
Site (Pittsburgh) 1466 (49.7) 
Age 73.6 +(2.9 
Education 
Post secondary 
High school graduate 
< High school 
 
1260 (42.7) 
954 (32.4) 
727 (24.9) 
Married 1531 (52.0) 
Health Behaviors  
Current smoker 302 (10.2) 
Alcohol use (≥1 drink per week) 847 (28.7) 
Health Status  
Pulmonary disease 298 (10.1) 
Arthritis 1650 (56.0) 
Urinary problems 495 (16.8) 
Cerebrovascular disease 231 (7.8) 
Bodily pain (any in past 30 days) 
 
 
 
1942 (65.9) 
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Table 1 (continued). Characteristics of the Sample at Baseline – Antihypertensives 
(n=2948) 
Variables Mean + SD or N, % 
Vision problems 
Excellent/Good sight 
Fair sight 
Poor to completely blind 
 
2346 (79.6) 
519 (17.6) 
81 (2.8) 
Body Mass Index 
Underweight/Normal (<24.9) 
Overweight (25.0-29.9) 
Obese (30+) 
 
947 (32.2) 
1257 (42.6) 
744 (25.2) 
Excellent/Very good/Good self-rated health 2479 (84.1) 
Depressive symptoms (Short CES-D>10)
*
 168 (5.7) 
Cognitive impairment (3MS<80)
*
 284 (9.6) 
Drugs that increase risk of falls
*
 
(benzodiazepines, antipsychotics, opioids) 
367 (12.5) 
 
No. prescription medications
*, †
   1.8 + 2.0 
Health Status [conditions for which antihypertensives 
are prescribed] 
 
Self-reported hypertension
*
 
Controlled 
Uncontrolled 
 
775 (26.3) 
723 (24.5) 
Peripheral arterial disease 149 (5.1) 
Benign prostatic hyperplasia 
 
692 (23.5) 
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Table 1 (continued). Characteristics of the Sample at Baseline - Antihypertensives 
(n=2948) 
Variables Mean + SD or N, % 
Coronary heart disease 631 (21.4) 
Congestive heart disease 85 (2.9) 
Diabetes 440 (14.9) 
Access to Care  
Hospitalization in previous 12 months 435 (14.8) 
Private physician 2319 (78.7) 
Prescription Insurance 1861 (63.1) 
Flu shot in previous 12 months 2039 (69.2) 
*
Time –varying 
†
Excluding drugs that increase falls and antihypertensives 
Abbreviations: 3MS = Modified Mini-Mental Status Exam; CES-D = Center for Epidemiologic Studies 
Depression Scale; CNS= central nervous system; SD= standard deviation 
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Table 2. Antihypertensive Use Over Time* 
Antihypertensive 
Medication Use 
Year 1 
(n=2948) 
N(%) 
Year 2 
(n=2811) 
N(%) 
Year 3 
(n=2679) 
N(%) 
Year 5 
(n=2489) 
N(%) 
Year 6 
(n=2388) 
N(%) 
Any use 1677 
(56.9) 
1636 
(58.2) 
1622 (60.5) 1676 (67.3) 1673 (70.1) 
Long term (≥2 years) for 
any use 
1143/1677 
(68.2) 
1084/1636 
(66.3) 
1073 (66.2) 1153/1676 
(68.8) 
1059/1673 
(63.3) 
SDD ≥2 283 (9.6) 289 (10.3) 253 (9.4) 300 (12.4) 305 (12.8) 
SDD 1-2 546 (18.5) 555 (19.7) 584 (21.8) 668 (26.8) 662 (27.7) 
SDD <1 820 (28.7) 774 (28.1) 770 (29.3) 703 (28.4) 695 (29.6) 
Specific class use 
Beta blockers 
Alpha blockers 
Loop diuretics 
Thiazide diuretics 
Potassium-sparing 
diuretics 
Calcium channel blockers 
ACE inhibitors 
ARB 
Vasodilators 
-- 
395 (13.4) 
364 (12.4) 
178 (6.0) 
582 (19.7) 
258 (13.2) 
 
678 (23.0) 
443 (15.0) 
69 (2.3) 
35 (1.2) 
-- 
409 (14.5) 
317 (11.3) 
195 (6.9) 
593 (21.1) 
257 (9.1) 
 
662 (23.6) 
458 (16.3) 
95 (3.4) 
20 (0.7) 
-- 
434 (16.2) 
284 (10.6) 
207 (7.7) 
557 (20.8) 
239 (8.9) 
 
642 (24.0) 
479 (17.9) 
142 (5.3) 
18 (0.7) 
-- 
520 (20.9) 
264 (10.6) 
263 (10.6) 
599 (24.1) 
230 (9.2) 
 
631 (25.4) 
586 (23.5) 
205 (8.2) 
9 (0.4) 
-- 
572 (24.0) 
238 (10.0) 
265 (11.1) 
579 (24.3) 
208 (8.7) 
 
611 (25.6) 
606 (25.4) 
249 (10.4) 
10 (0.4) 
Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blocker; SDD = 
standardized daily dose of antihypertensives 
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*No medication data were collected at year 4 in the Health ABC Study 
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Table 3. Association between Antihypertensive Use and Recurrent Falls Controlling for Covariates 
Antihypertensive Medication Use
*
 Adj. OR (95% CI)
 †
 
Any use 1.13 (0.88-1.46) 
Long duration (≥2 years) 1.15 (0.88-1.49) 
Short duration 1.11 (0.83-1.49) 
SDD ≥2 1.21 (0.82-1.78) 
SDD 1-2 1.05 (0.78-1.42) 
SDD <1 1.16 (0.88-1.52) 
Specific Class Use
‡
  
Beta blockers 1.06 (0.82-1.36) 
Alpha blockers 1.25 (0.94-1.67) 
Loop diuretics 1.50 (1.11-2.03) 
Thiazide diuretics 0.87 (0.68-1.10) 
Potassium-sparing diuretics 0.81 (0.56-1.17) 
Calcium channel blockers 1.06 (0.84-1.33) 
ACE inhibitors 1.10 (0.85-1.42) 
ARBs 1.17 (0.80-1.71) 
Abbreviations: ACE = angiotensin converting enzyme; adj=adjusted; ARB = angiotensin II receptor 
blocker; CI=confidence interval; OR=odds ratio 
*
Reference group is No Use  
†
Controlling for variables forced into the model (i.e., site, heart failure, BPH, cognitive impairment, 
depressive symptoms, self-reported hypertension (controlled/uncontrolled), drugs that increase risk of 
falls) and those from forward selection procedures (i.e., education, age, marital status, alcohol use, 
cerebrovascular disease, diabetes, pulmonary disease, arthritis, urinary problems, vision problems, total 
number of prescription medications, syncope) 
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‡
Each antihypertensive sub-class was run as a separate model and controlled for antihypertensive sub-
class use other than the sub-class being evaluated. 
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Table 4. Multivariable Association between Antihypertensive Use and Recurrent Falls Restricted to 
those with Self-Reported Hypertension and Stratified by Blood Pressure Control 
 Self-reported 
Hypertension 
(n=1498) 
Controlled 
(n=775) 
Uncontrolled 
(n=723) 
Antihypertensive 
Medication Use
*
 
Adj. OR (95% CI)
 †
 Adj. OR (95% CI)
 †
 Adj. OR (95% CI)
 †
 
Any use 0.99 (0.70-1.42) 0.90 (0.57-1.41) 1.02 (0.62-1.69) 
Long duration (≥2 years) 0.96 (0.67-1.38) 0.89 (0.56-1.40) 1.00 (0.60-1.68) 
Short duration 1.05 (0.71-1.56) 0.93 (0.55-1.57) 1.06 (0.60-1.85) 
SDD ≥2 1.07 (0.68-1.67) 0.86 (0.47-1.57) 1.20 (0.66-2.20) 
SDD 1-2 0.93 (0.63-1.36) 0.71 (0.43-1.16) 1.05 (0.60-1.84) 
SDD <1 0.99 (0.68-1.46) 1.06 (0.65-1.72) 0.88 (0.51-1.52) 
Specific Class Use
‡
    
Beta blockers 1.18 (0.90-1.54) 1.05 (0.72-1.52) 1.29 (0.88-1.91) 
Alpha blockers 1.20 (0.87-1.66) 1.15 (0.76-1.73) 1.12 (0.70-1.96) 
Loop diuretics 1.45 (1.02-2.06) 1.47 (0.92-2.37) 1.48 (0.90-2.44) 
Thiazide diuretics 0.91 (0.71-1.16) 0.77 (0.54-1.11) 1.02 (0.72-1.44) 
Potassium-sparing diuretics 0.76 (0.51-1.14) 0.72 (0.42-1.21) 0.88 (0.48-1.61) 
Calcium channel blockers 1.04 (0.81-1.32) 0.87 (0.62-1.23) 1.18 (0.85-1.64) 
ACE inhibitors 1.10 (0.83-1.45) 1.20 (0.83-1.73) 1.06 (0.73-1.53) 
ARBs 1.19 (0.82-1.73) 0.94 (0.54-1.64) 1.31 (0.78-2.20) 
Abbreviations: ACE = angiotensin converting enzyme; adj=adjusted; ARB = angiotensin II receptor 
blocker; CI=confidence interval; OR=odds ratio; MV=multivariable 
*
Reference group is No Use  
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†
Controlling for variables forced into the model (i.e., site, heart failure, BPH, cognitive impairment, 
depressive symptoms, drugs that increase risk of falls) and those from forward selection procedures (i.e., 
age, alcohol use, cerebrovascular disease, diabetes, pulmonary disease, arthritis, vision problems, total 
number of prescription medications) 
‡
Each antihypertensive sub-class was run as a separate model and controlled for antihypertensive sub-
class use other than the sub-class being evaluated. 
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Table 5. Multivariable Association between Antihypertensive Use and Recurrent Falls Stratified by 
History of Falls at Baseline (n=2948) 
 History of Falls 
(n=632) 
No History of Falls 
(n=2316) 
Antihypertensive Medication Use
*
 Adj. OR (95% CI)
 †
 Adj. OR (95% CI)
 †
 
Any use 0.93 (0.51-1.70) 0.68 (0.39-1.17) 
Long duration (≥2 years) 0.83 (0.43-1.60) 0.80 (0.45-1.41) 
Short duration 1.10 (0.54-2.22) 0.47 (0.23-0.96) 
SDD ≥2 1.22 (0.50-3.01) 0.55 (0.23-1.33) 
SDD 1-2 0.77 (0.35-1.70) 0.67 (0.34-1.30) 
SDD <1 0.97 (0.51-1.86) 0.71 (0.39-1.26) 
Specific Class Use
‡
   
Beta blockers 0.69 (0.33-1.43) 1.13 (0.63-2.03) 
Alpha blockers 1.49 (0.69-3.23) 1.00 (0.50-2.02) 
Loop diuretics 1.52 (0.93-2.48) 1.50 (1.00-2.23) 
Thiazide diuretics 1.01 (0.54-1.92) 0.55 (0.31-0.99) 
Potassium-sparing diuretics 0.90 (0.37-2.21) 0.90 (0.43-1.87) 
Calcium channel blockers 1.31 (0.74-2.35) 1.14 (0.70-1.85) 
ACE inhibitors 0.66 (0.31-1.42) 0.77 (0.43-1.39) 
ARBs 0.97 (0.29-3.22) 1.55 (0.45-5.4) 
Abbreviations: ACE = angiotensin converting enzyme; adj=adjusted; ARB = angiotensin II receptor 
blocker; CI=confidence interval; OR=odds ratio; MV=multivariable 
*
Reference group is No Use  
†
Controlling for variables forced into the model (i.e., site, heart failure, BPH, cognitive impairment, 
depressive symptoms, self-reported hypertension (controlled/uncontrolled), drugs that increase risk of 
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falls) and those from forward selection procedures (i.e., education, age, marital status, alcohol use, 
cerebrovascular disease, diabetes, pulmonary disease, arthritis, urinary problems, vision problems, total 
number of prescription medications, syncope) 
‡
Each antihypertensive sub-class was run as a separate model and controlled for antihypertensive sub-
class use other than the sub-class being evaluated. 
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3.0  ANTICHOLINERGIC USE AND RECURRENT FALLS IN COMMUNITY-
DWELLING OLDER ADULTS: FINDINGS FROM THE HEALTH ABC STUDY 
3.1 INTRODUCTION 
Anticholinergic medication use has been reported to be as high as 25% among 
community-dwelling older adults.
34-36
 Older adults may be more susceptible to anticholinergic 
adverse effects due to several reasons. One is decreased systemic clearance of many 
anticholinergic drugs. For example, because of age-related decreases in hepatic metabolism and 
systemic clearance, the half-life of cyclobenzaprine in older adults, a well-known skeletal muscle 
relaxant with strong anticholinergic effects, is nearly twice as long as that seen in their younger 
counterparts.
37
 Another reason is the decrease in central cholinergic activity due to decreased 
levels of acetylcholine synthesis or the number of acetylcholine receptors. This may account for 
the increased pharmacodynamic sensitivity seen in older adults with anticholinergic exposure.
38
 
In addition, there is evidence of increased blood-brain barrier permeability to drugs, including 
anticholinergics, in older adults. Finally, there is a reduction in P-glycoprotein activity as an 
efflux pump to transport drugs, including anticholinergics, out of the aged brain.
39
 These reasons 
make older adults more vulnerable to anticholinergic adverse effects. 
One such adverse effect that may occur from anticholinergic use is falling. Of note, 18-
40% of community-dwelling elderly fall yearly
10-12
, of whom nearly 50% have recurrent 
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falls.
12,13
 While it is generally accepted that anticholinergic use can lead to a fall, to date the 
results from studies assessing the association between anticholinergic use and falls are 
mixed.
35,40-42
 More specifically, direct evidence of the association between the use of 
anticholinergic medications and falls among community-dwelling older adults is limited.
35,42
 
Furthermore, because in the US over-the-counter (OTC) medication data are not available in 
administrative pharmacy claims, there is limited prior literature taking this type of medication 
exposure into account. Thus, a definitive answer to the association between the use of 
anticholinergic medications and falls in older patients deserves further study. Accordingly, the 
immediate objective is to conduct a thorough longitudinal analysis to assess the association 
between anticholinergic use across multiple anticholinergic sub-classes and recurrent falls. 
3.2 METHODS 
3.2.1 Study design, data source, and sample 
This longitudinal study used data from the Health, Aging, and Body Composition (Health ABC) 
study, a population-based, prospective, observational study of community-dwelling older adults. 
This study was approved by the University of California at San Francisco (UCSF), University of 
Pittsburgh, and University of Tennessee Memphis Institutional Review Boards, and informed 
consent was obtained from each participant prior to data collection. The baseline sample 
included 3,075 Black and White men and women aged 70-79 years who reported no difficulty 
walking ¼ mile, or climbing 10 steps and lived in specified zip codes surrounding Pittsburgh, PA 
and Memphis, TN.
5
 The sample for the current analysis included 2,948 older adults at year 1 
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with complete medication use and fall data the following year followed through year 6 for 
anticholinergic medications and year 7 for recurrent falls. 
3.2.2 Data collection and management 
Participants were seen annually during a clinic or home visit and detailed physiologic and self-
report questionnaire measurements (including demographics, health behavior/status (including 
medications), and access to health care factors) were collected.
5
 Detailed medication data were 
collected in clinic or at home about products taken in the previous month using a state of the art 
―brown bag‖ review method.16,17 A similar data collection approach was used for telephone 
interviews if they were unable to be seen in person. Studies have shown that medication use 
information collected by either the ―brown bag‖ or telephone methods is highly accurate and 
concordant with information about dispensed prescription drugs in claims data.
18,19
 For all 
medications, the interviewer recorded the name, strength, prescription type (prescription or over-
the-counter), dosage form, and the number of dosage forms the respondents said they had used 
the previous day, week, or month. The medication data collected for the Health ABC Study were 
edited and coded using the Iowa Drug Information System (IDIS) Drug Vocabulary and 
Thesaurus.
16
 IDIS is a hierarchical coding system with 8 character unique codes for specific drug 
ingredients, chemical and therapeutic categories. This therapeutic category code allows drugs to 
be assigned to one of 20 major therapeutic classes and 200 sub-classes that are based upon an 
expanded version of the American Hospital Formulary Services format.
20
 
Teleform was used to create scannable forms for direct data entry. Missing and 
questionable values were highlighted by the software for visual review and online editing. 
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Additional ranges checks and data cleaning were conducted at the UCSF Coordinating Center. 
De-identified SAS® data files were created for purposes of analyses. 
3.2.3 Primary outcome 
The number of falls in which the participant landed on the floor or ground in the previous twelve 
months was assessed at the year following medication use data collection (e.g., year 1 
antihypertensive use and year 2 falls) for each wave (five waves). The primary outcome was 
recurrent falls (≥ two) in the ensuing 12 months following report of medication use. This method 
of fall recall (in the previous 12 months) has been shown to be highly specific (91% – 95%) in 
comparison with that reported using more frequent assessments.
21
 Recurrent falls (as opposed to 
single falls) may be more clinically important since they can be a marker for those with an 
increased risk of physical and cognitive status problems, and other morbidity and mortality in the 
elderly.
12
 
3.2.4 Primary independent variable 
Medications with anticholinergic properties were grouped based on the 2012 AGS Beers Criteria 
for Potentially Inappropriate Medication Use in Older Adults into the following therapeutic 
classes: 1) antiemetic / antivertigo / antihistamine (IDIS codes: 4000003, 4000006, 4000010, 
4000012, 4000018, 4000054, 4000061, 4000068, 4000078, 4000079, 4000083, 4000084, 
4000091, 4000099, 12080009, 28160807, 56220003, 56220005, 56220096); 2) antidepressant / 
antipsychotic (IDIS codes: 28160601, 28160602, 28160650, 28160681, 28160688, 28160689, 
28160695, 28160702, 28160836, 28160858, 28160912, 28160913, 56220089); 3) 
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gastrointestinal / urinary antispasmodics (IDIS codes: 12080001, 12080005, 12080008, 
12080009, 12080039, 12080047, 12080079, 52240008, 86000004, 86000047); and 4) 
miscellaneous (skeletal muscle relaxants, antiparkinson agents, and cardiac) (IDIS codes: 
12080802, 12080804, 12080806, 12200009, 24040024).
43
 Any use was defined as the use of any 
medication contained in these 4 classes. To evaluate the possibility of a dose-response 
relationship, we used a previously published approach; the daily dose was calculated for current 
users for each individual anticholinergic medication by multiplying the number of dosage forms 
taken the previous day by the strength of the medication reported at the interview.
13
 The daily 
dose was then converted to a standardized daily dose (SDD) by dividing it by the minimum 
effective dose per day as noted in standard references.
44
 Thus, a person taking 1.0 standardized 
anticholinergic drug unit would have taken the minimum recommended effective daily dose for 
one agent. The standardized dose was summated for all anticholinerigcs, regardless of class, 
taken daily. Finally, to examine the impact of duration, long-term use was operationally defined 
as ≥ 2 years and short-term use as < 2 years.13 
3.2.5 Control variables 
To address potential confounding, we controlled for a number of demographic, health 
status/behavior, and access to care factors.
12,13
 Demographic factors included age, sex, race, site, 
education (less than a high school education, high school graduate, and post-secondary 
education), and marital status (never married, married, previously married). 
Health behavior factors included current smoking status and alcohol use. Health status 
factors included self-reported pulmonary disease, urinary problems, coronary heart disease, 
congestive heart disease, cerebrovascular disease, diabetes, hypertension, peripheral artery 
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disease, hearing impairment, vision (excellent/good sight, fair sight, and poor to completely 
blind), and body mass index (underweight/normal, <24.9; overweight, 25.0-29.9; and obese, 
≥30). Self-rated global health was dichotomized as excellent/very good/good vs. fair/poor. We 
created a time-varying dichotomous variable for exposure to any drug that increases the risk of 
falls (non-anticholinergic central nervous system medications, including benzodiazepines, 
antipsychotics, opioids).
13
 A continuous time-varying variable was created for the total number 
of prescription medications (excluding dugs that increase falls, and anticholinergic drugs) per 
participant. Access to care factors included dichotomous variables for hospitalization in previous 
12 months, private physician, prescription insurance, and flu shot in previous 12 months.
25
 
Anticholinergics can be used for a number of conditions. Therefore, to control for 
potential confounding by indication we created time-varying dichotomous variables for 
depressive symptoms (Short Center for Epidemiologic Studies-Depression Scale >10) – for 
which tricyclic antidepressants may be used
23
; cognitive impairment (The Modified Mini-Mental 
State Test [3MS] <80) – for which antipsychotics may be used to treat the behavioral symptoms 
of cognitive impairment
24
; back pain in past 12 months – for which skeletal muscle relaxants 
may be used; anxiety symptoms – for which several anticholinergic agents may be used; and 
sleep problems – for which antihistamines may be used.13 
3.2.6 Statistical analysis 
We used appropriate descriptive statistics for summarization and generalized estimating 
equations (GEE) for eliciting the main findings.
26-28
 First, we assessed the unadjusted association 
between anticholinergic use and recurrent falls over time. Second, a priori covariates that may 
affect recurrent falls were included: site, cognitive impairment, depressive symptoms, non-
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anticholinergic drugs that increase the risk of falls, urinary problems, back pain, and sleep 
problems. Each anticholinergic sub-class was run as a separate model and controlled for 
anticholinergic sub-class use other than the sub-class being evaluated. Finally, additional 
covariates were selected using a forward stepwise selection approach applied separately for each 
of three domains of covariates (demographic, health status/behavior, and access to health care). 
Specifically, stepwise detected covariates and those deemed important a priori were included in 
the final GEE model. All analyses were conducted using SAS
®
 software (version 9.3; SAS 
Institute, Cary, NC) with GENMOD procedure to obtain main results. 
3.3 RESULTS 
At baseline, the mean (standard deviation) age was 73.6 (2.9) years, 51.6% were female, 
and 40.8% were black (Table 6). In addition, approximately 40% reported back pain in the past 
12 months, and the vast majority had excellent/very good/good self-reported health. Baseline 
characteristics of anticholinergic users versus nonusers are shown in Table 1. The groups were 
found to have several differences. For example, anticholinergic users were more likely to have 
fair/poor self-rated health, urinary problems, back pain the past 12 months, sleep problems, 
anxiety symptoms, and depressive symptoms.   
Table 7 shows the prevalence of anticholinergic use over time. At baseline, 16% reported 
the use of one or more anticholinergics, with antiemetic / antivertigo / antihistamine being the 
most common class used (9.8%). At baseline, half took an anticholinergic for > 2 years and half 
for < 2 years, with three-fourths taking them in doses ≤ 2 SDDs. By year 6, the prevalence of 
anticholinergic use remained consistent at 15.8%, with antiemetic / antivertigo / antihistamine 
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remaining the most common category used (6.6%). Moreover, at year 2, 8% of participants 
reported having ≥ 2 falls in the previous year. This rate remained somewhat stable over the next 
four waves (7.5 to 10.4%). 
Table 8 shows the results of the multivariable GEE analyses, controlling for potential 
demographic, health status/behavior, and access to care factors. Adjusted modeling revealed no 
statistically significant increase in risk of recurrent falls in older anticholinergic users (adjusted 
OR 1.34, 95% CI 0.93-1.93). Similarly, no increase in risk was found among those taking higher 
SDDs or those with longer duration of use. In addition, none of the 3 anticholinergic sub-classes 
were found to be significantly associated with recurrent falls. Finally, Table 9 shows the results 
of the multivariable GEE analyses, controlling for key covariates forced into the model, 
including and not including the important variable, cognitive impairment. Similar point estimates 
were seen compared to the fully adjusted model as well as between these two models. 
3.4 DISCUSSION 
This study presents some of the first data to longitudinally assess the association between 
anticholinergic use – measured via detailed dosage and duration data and including both 
prescription and OTC drug use – and recurrent falls in community-dwelling older adults. We 
found no statistically significant association between any anticholinergic use and recurrent falls 
after adjusting for important potential confounders. In addition, we did not find a statistically 
significant association between anticholinergic dose or duration response and recurrent falls. 
 These findings are consistent with a study of community-dwelling older Canadians using 
10 years of prospective data from the Canadian Multicentre Osteoporosis Study (MaMos).
42
 
 37 
Fraser et al sought to determine if anticholinergic medication use was associated with falls in 
7,753 participants (mean age, 71.1 years for anticholinergic users vs. 66.7 years for nonusers).
42
 
They found that unadjusted anticholinergic use was associated with falls (OR=1.50, 95% 
CI=1.14-1.98), but the association was no longer significant after covariate adjustment (adjusted 
OR=1.25, 95% CI=0.91-1.72).
42
 Similar results occurred at years 5 and 10. It is important to note 
that this study used any fall as the primary outcome, whereas our study used recurrent falls, and 
that the Fraser et al study conducted three cross-sectional analyses without using longitudinal 
analyses (e.g., GEE).
42
 Despite these differences, our findings are essentially the same.  
 Previous studies have reported anticholinergic use to be significantly associated with falls 
in older adults
40,41
, and there is biologic plausibility to support the mechanism by which this 
could occur. For example, anticholinergic medications are known to cause dizziness and 
lightheadedness, and pharmacokinetic/ pharmacodynamic changes in older adults increase their 
risk for such side effects. Thus, a logical explanation exists for an association between 
anticholinergic use and falls in older adults, which has been perpetuated for years in clinical and 
research settings. However, the literature on the association between anticholinergic use and falls 
in community-dwelling older adults is mixed.
35,40-42
 One possible reason for this lack of clarity 
may be because previous studies have not controlled for underlying medical conditions for which 
anticholinergic medications are used (e.g., back pain, depression, cognitive impairment). The 
potential for confounding by indication is a major threat to studies assessing medication use in 
older adults. To address this, we controlled for key conditions for which older adults might use 
anticholinergics. Taken together, our findings in addition to the results from Fraser et al suggest 
that after controlling for these important underlying medical conditions for which anticholinergic 
medications might be used, there is no statistically significant association between 
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anticholinergic drugs and falls in community-dwelling elders.
42
 Simply put, while anticholinergic 
drugs should generally be avoided in the elderly, individual risks and benefits for each patient 
should be considered.
35
 
 Moreover, although we did not assess drug-disease interactions in this study, one could 
presume that the older adults at highest risk for falls are those with underlying medical 
conditions that independently increase the risk of falling (e.g., depression, cognitive impairment). 
Therefore, older adults with these conditions should be carefully monitored if they are receiving 
an anticholinergic medication. This approach is supported by the AGS Beers Criteria, which 
identify important drug-disease interactions involving anticholinergic medications.
43
 
There are important potential limitations to our study. First, the question of statistical 
power may be a concern. In order to assess the power available in the current study, we 
conducted a power assessment. We base the power assessment on a test of unadjusted 
association between the measure of any anticholinergic use and the primary outcome, previously 
published literature, and our prior analyses of Health ABC Study data. We had found that 
medication data with subsequent falls data (the following year) had been available for 2948, 
2811, 2679, 2489, and 2449 participants at years 1, 2, 3, 5, and 6, respectively. The proportion of 
any anticholinergic drug use was 14-16% at any given year, and 7-10% of participants had 
experienced recurrent falls. Due to the potential correlation between the years of the same 
participants, we conservatively assumed the above 13,376 observations effectively contain 
information from half as many independent observations or 6,688 (i.e., design effect of 2). Given 
these parameters, we would have been able to detect statistical significance of an odds ratio as 
small as 1.35 with 80% power in a two-tailed test at the alpha=0.05 level for the any 
anticholinergic use measure and the primary outcome. Given that the point estimate for our main 
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finding was also 1.34 and the fact that we did not observe the combination of a high odds ratio 
and a very wide confidence interval, it is unlikely that lack of statistical power played a major 
role in arriving at our conclusion. However, a prospectively designed study with adequate 
statistical power is needed to arrive at definitive conclusions. 
Second, the main outcome of recurrent falls was retrospectively collected via self-report. 
However, it is a highly specific method in comparison to self-reporting of falls via diary.
21
 Third, 
medication data were collected at fixed annual assessments, preventing us from documenting the 
exact date in which anticholinergics were initiated, changes, or discontinued. Fourth, while it is 
possible that there is residual confounding, we were mindful of potential confounding bias and 
adjusted for common indications for anticholinergic therapy. Finally, our analysis focused on 
older, well-functioning community-dwelling Black and White men and women from the 
Memphis and Pittsburgh areas, and the generalizability to older adults in other regions or 
different care settings is unknown.  
In conclusion, increased point estimates suggest an association of anticholinergic use 
with recurrent falls, but the associations did not reach statistical significance. Future studies are 
needed to examine other measures of anticholinergic burden, and their associations with other 
outcomes such as cognitive function. 
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Table 6. Characteristics of the Sample at Baseline - Anticholinergics (n=2948) 
Variables Anticholinergic use,  
mean + SD or N (%) 
(n = 467) 
No anticholinergic 
use,  
mean + SD or N (%) 
(n = 2481) 
P value 
Sociodemographics    
Female gender 308 (65.9) 1214 (48.9) <0.0001 
Black race 160 (34.3) 1043 (42.0) 0.002 
Age, mean (SD) 73.6 (2.8) 73.6 (2.9) 0.71 
Pittsburgh site 189 (40.5) 1277 (51.5) <0.0001 
Education 
Post secondary  
High school 
graduate 
< High school  
 
211 (45.2) 
153 (32.8) 
102 (21.8) 
 
1049 (42.3) 
801 (32.3) 
625 (25.2) 
0.274 
Married 208 (44.5) 1323 (53.3) <0.001 
Health 
Behaviors/Status  
   
Current smoker 52 (11.1) 250 (10.1) 0.493 
Alcohol use (≥1 
drink per week) 
 
126 (27.0) 
 
721 (29.1) 
0.363 
Pulmonary disease 60 (12.9) 238 (9.6) 0.032 
Urinary problems
*
 213 (45.6) 928 (37.4) 0.001 
Coronary heart 
disease 
94 (20.1) 537 (21.6) 0.459 
Congestive heart 
disease 
11 (2.4) 74 (3.0) 0.463 
Cerebrovascular 
disease 
43 (9.2) 188 (7.6) 0.229 
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Diabetes  70 (15.0) 370 (14.9) 0.974 
Hypertension 232 (49.7) 1266 (51.0) 0.593 
Peripheral arterial 
disease  
21 (4.5) 128 (5.2) 0.522 
Hearing impairment 42 (9.0) 220 (8.9) 0.923 
Vision problems 
Excellent/good sight 
Fair sight     
Poor to completely 
blind 
 
375 (80.3) 
85 (18.2) 
7 (1.5) 
 
1971 (79.4) 
434 (17.5) 
74 (3.0) 
0.193 
Body Mass Index 
Underweight/normal 
(<24.9) 
Overweight (25.0-
29.9) 
Obese (30+) 
 
158 (33.8) 
183 (39.2) 
126 (27.0) 
 
789 (31.8) 
1074 (43.3) 
618 (24.9) 
0.256 
Self-rated health 
Excellent/very 
good/good 
Fair/poor 
 
378 (80.9) 
89 (19.1) 
 
2101 (84.7) 
376 (15.2) 
0.035 
Drugs that increase 
risk of falls 
(benzodiazepines, 
antipsychotics, 
opioids)
*
 
 
167 (35.8) 
 
218 (8.8) 
<0.0001 
Number of 
prescription 
medications
*,† 
 
 
 
2.1 (2.4) 1.7 (1.9) 0.0001 
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Health Status [conditions for which anticholinergics are prescribed] 
Depressive 
symptoms 
(Short CES-D>10)
*
  
40 (8.6) 128 (5.2) 0.003 
Cognitive 
impairment 
(3MS<80)
*
 
29 (6.2) 255 (10.3) 
 
0.006 
Back Pain in past 12 
months
*
 
 
224 (48.0) 
 
1017 (41.0) 
 
0.005 
Anxiety symptoms
*
 100 (21.4) 314 (12.7) <0.0001 
Sleep problems
*
 135 (28.9) 556 (22.4) 0.002 
Access to Health 
Care 
   
Hospitalization in 
previous 12 months 
89 (19.1) 346 (14.0) 0.004 
Private physician 382 (81.8) 1937 (78.1) 0.071 
Prescription 
insurance 
294 (63.0) 1567 (63.2) 0.939 
Flu shot in previous 
12 months 
339 (72.6) 1700 (68.5) 0.081 
*
Time-varying 
†
Excluding drugs that increase risk of falls and anticholinergic drugs 
Abbreviations: 3MS = Modified Mini-Mental Status Exam; CES-D = Center for Epidemiologic Studies 
Depression Scale; CNS= central nervous system; SD= standard deviation 
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Table 7. Anticholinergic Use over Time* 
Anticholinergic 
Medication Use 
Year 1 
(n=2948) 
n, % 
Year 2 
(n=2811) 
n, % 
Year 3 
(n=2679) 
n, % 
Year 5 
(n=2489) 
n, % 
Year 6 
(n=2388) 
n, % 
Any Use 471 (16.0) 402 (14.3) 375 (14.0) 384 (15.4) 378 (15.8) 
ACSD >2 120 (25.5) 118 (29.4) 102 (27.2) 79 (20.6) 95 (25.1) 
ACSD 1-2 161 (34.2) 150 (37.3) 163 (43.5) 189 (49.2) 188 (49.7) 
ACSD <1 190 (40.3) 134 (33.3) 110 (29.3) 116 (30.2) 95 (25.1) 
Long term use (>2 years) 232 (49.3) 180 (44.8) 160 (42.7) 187 (48.7) 160 (42.3) 
Short term use 239 (50.7) 222 (55.2) 215 (57.3) 197 (51.3) 218 (57.7) 
Specific class use*   
Antiemetic / antivertigo / 
antihistamines 
Antidepressants / 
antipsychotics  
GI / urinary antispasmodics   
Miscellaneous: SMR / 
Antiparkinson / Cardiac 
-- 
290 (9.8) 
118 (4.0) 
70 (2.4) 
26 (0.9) 
-- 
197 (7.0) 
112 (4.0) 
106 (3.8) 
23 (0.8) 
-- 
183 (6.8) 
109 (4.1) 
94 (3.5) 
23 (0.9) 
-- 
177 (7.1) 
99 (4.0) 
127 (5.1) 
15 (0.6) 
-- 
158 (6.6) 
107 (4.5) 
138 (5.8) 
15 (0.6) 
*
Medication data were not collected at year 4 in the Health ABC Study  
Abbreviations: ACSD: anticholinergic standardized dose; GI: gastrointestinal; SMR: skeletal 
muscle relaxant  
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Table 8. Association between Anticholinergic Use and Recurrent Falls Controlling for Covariates 
Anticholinergic Medication Use
*
 Adjusted OR (95% CI)
†
 
Any Use 1.34 (0.93-1.93) 
Long duration (≥2 years) 1.36 (0.84-2.21) 
Short duration 1.32 (0.83-2.10) 
SDD – ≥2 1.54 (0.84-2.82) 
SDD – 1-2 1.40 (0.80-2.45) 
SDD – <1 1.17 (0.68-2.00) 
Specific Class Use
‡
  
Antiemetic / antivertigo / antihistamines 1.40 (0.91-2.13) 
Antidepressants / antipsychotics 1.14 (0.59-2.18) 
Gastrointestinal / urinary antispasmodics and 
Miscellaneous 
1.26 (0.64-2.48) 
Abbreviations: OR=odds ratio; CI=confidence interval 
*
Reference group is No Use 
 
†
Controlling for variables forced into the model (i.e., site, cognitive impairment, depression, 
drugs that increase the risk of falls, urinary problems, back pain, and sleep problems) and those 
from forward selection procedures (i.e., smoking, alcohol use, cerebrovascular disease, diabetes, 
vision problems, anxiety, and total number of prescription medications) 
‡
Each anticholinergic sub-class was run as a separate model and controlled for anticholinergic 
sub-class use other than the sub-class being evaluated 
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Table 9. Association between Anticholinergic Use and Recurrent Falls Controlling for Key 
Covariates – Including and Not Including Cognitive Impairment 
Anticholinergic Medication Use
*
 Including Cognitive 
Impairment –  
Adjusted OR (95% CI)
†
 
Not Including Cognitive 
Impairment –  
Adjusted OR (95% CI)
†
 
Any Use 1.40 (0.99-1.99) 1.40 (0.99-1.98) 
Long duration (≥2 years) 1.42 (0.90-2.22) 1.41 (0.90-2.22) 
Short duration 1.39 (0.89-2.19) 1.38 (0.88-2.17) 
SDD – ≥2 1.82 (1.02-3.23) 1.82 (1.02-3.23) 
SDD – 1-2 1.42 (0.83-2.43) 1.42 (0.83-2.42) 
SDD – <1 1.16 (0.69-1.97) 1.15 (0.68-1.95) 
Specific Class Use
‡
 -- -- 
Antiemetic / antivertigo / 
antihistamines 
1.38 (0.92-2.07) 1.37 (0.92-2.06) 
Antidepressants / antipsychotics 1.23 (0.66-2.31) 1.24 (0.66-2.31) 
Gastrointestinal / urinary 
antispasmodics and Miscellaneous 
1.59 (0.83-3.04) 1.58 (0.83-3.03) 
 
*
Reference group is No Use 
 
†
Controlling for variables forced into the model (i.e., site, depression, drugs that increase the risk 
of falls, urinary problems, back pain, and sleep problems) 
‡
Each anticholinergic sub-class was run as a separate model and controlled for anticholinergic 
sub-class use other than the sub-class being evaluated 
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4.0  ANTIDEPRESSANT USE AND RECURRENT FALLS IN COMMUNITY-
DWELLING OLDER ADULTS: FINDINGS FROM THE HEALTH ABC STUDY 
4.1 INTRODUCTION 
Falls and depressive symptoms are common in older adults and pose a significant burden 
on the healthcare system and society.
45
 Prevalence of mild depressive symptoms in older adults 
has been estimated to be 15% for community populations; major clinical depression is less 
common, with a prevalence of 0.4% to 2%.
45
 Several studies have reported associations between 
depressive symptoms and falls in older adults, and it has been suggested that common pathways 
for both conditions can explain such associations. Although many older adults with symptoms of 
depression are not treated, the pharmacologic treatment for depression with antidepressants has 
also been consistently associated with risk of falls.
46
 Antidepressants are thought to contribute to 
falls through several different mechanisms although the exact mechanisms are not known. While 
selective serotonin reuptake inhibitors (SSRIs) were originally thought to be safer alternatives to 
the tricyclic antidepressants (TCAs) regarding falls risk, the literature is mixed on their relative 
safety.
47
  
Furthermore, the magnitude of the increased risk of falling with an antidepressant is 
about the same as the excess risk found in patients with untreated depression.
47
 Moreover, when 
an antidepressant is necessary, the clinician needs to estimate the risk of falls consequent upon 
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prescribing or continuing with it, and to estimate the relative risks of falls with difference classes 
of drug. Many patients with a history of depression are maintained on an antidepressant over the 
long term but might be able to manage without drug treatment. In cases where the depression has 
been a major illness or has been recurrent, it may be necessary to continue with antidepressants, 
whatever the falls risk.
47
 Moreover, recurrent falls (as opposed to single falls) may be more 
clinically important since they can be a marker for those with an increased risk of physical and 
cognitive status problems, and other morbidity and mortality in the elderly (6). However, it is not 
clear what the comparative risk of falls is for various antidepressant agents among community-
dwelling older adults who have a history of a fall/fracture (i.e., those at the highest risk of future 
falls). Thus, a thorough longitudinal analysis is needed to assess the association between 
antidepressant use and the important outcome of recurrent falls, particularly among those with a 
history of falls/fractures. 
4.2 METHODS 
4.2.1 Study design, data source, and sample 
This longitudinal study used data from the Health, Aging, and Body Composition (Health 
ABC) study, a population-based, prospective, observational study of community-dwelling older 
adults. This study was approved by the University of California at San Francisco (UCSF), 
University of Pittsburgh, and University of Tennessee Memphis Institutional Review Boards, 
and informed consent was obtained from each participant prior to data collection. The baseline 
sample included 3,075 Black and White men and women aged 70-79 years who reported no 
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difficulty walking ¼ mile, or climbing 10 steps and lived in specified zip codes surrounding 
Pittsburgh, PA and Memphis, TN.
5
 The sample for the current analysis included 2,948 older 
adults at year 1 with complete medication use and fall data the following year followed through 
year 6 for antidepressant medications and year 7 for recurrent falls. 
 
4.2.2 Data collection and management 
Participants were seen annually during a clinic or home visit and detailed physiologic and 
self-report questionnaire measurements (including demographics, health behavior/status 
(including medications), and access to health care factors) were collected.
5
 Detailed medication 
data were collected in clinic or at home about products taken in the previous month using a state 
of the art ―brown bag‖ review method.16,17 A similar data collection approach was used for 
telephone interviews if they were unable to be seen in person. Studies have shown that 
medication use information collected by either the ―brown bag‖ or telephone methods is highly 
accurate and concordant with information about dispensed prescription drugs in claims data.
18,19
 
For all medications, the interviewer recorded the name, strength, dosage form, and the number of 
dosage forms the respondents said they had used the previous day, week, or month. The 
medication data collected for the Health ABC Study were edited and coded using the Iowa Drug 
Information System (IDIS) Drug Vocabulary and Thesaurus.
6
 IDIS is a hierarchical coding 
system with 8 character unique codes for specific drug ingredients, chemical and therapeutic 
categories. This therapeutic category code allows drugs to be assigned to one of 20 major 
therapeutic classes and 200 sub-classes that are based upon an expanded version of the American 
Hospital Formulary Services format.
20
 
 49 
Teleform was used to create scannable forms for direct data entry. Missing and 
questionable values were highlighted by the software for visual review and online editing. 
Additional ranges checks and data cleaning were conducted at the UCSF Coordinating Center. 
De-identified SAS® data files were created for purposes of analyses. 
4.2.3 Primary outcome 
The number of falls in which the participant landed on the floor or ground in the previous 
twelve months was assessed at the year following medication use data collection (e.g., year 1 
antihypertensive use and year 2 falls) for each wave (five waves). The primary outcome was 
recurrent falls (≥ two) in the ensuing 12 months following report of medication use. This method 
of fall recall (in the previous 12 months) has been shown to be highly specific (91% – 95%) in 
comparison with that reported using more frequent assessments.
21
 
4.2.4 Primary independent variable 
Antidepressant medications were grouped as follows: 1) selective serotonin reuptake 
inhibitors (SSRI) (IDIS codes: 28160701, 28160703, 28160704, 28160705, 28160702, 
28160711); 2) tricyclic antidepressants (TCA) (IDIS codes: 28160601, 28160602, 28160650, 
28160681, 28160688, 28160689, 28160695); and 3) others (bupropion, venlafaxine, mirtazapine, 
trazodone, phenelzine) (IDIS codes: 28160505, 28160434, 28160458, 28160617, 28160415). 
Any use was defined as the use of any medication contained in these 3 sub-classes. To evaluate 
the possibility of a dose-response relationship, the daily dose was calculated for current users for 
each individual antidepressant medication by multiplying the number of dosage forms taken the 
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previous day by the strength of the medication reported at the interview. The daily dose was then 
converted to a standardized daily dose (SDD) by dividing it by the minimum effective dose per 
day as noted in standard references.
44
 Thus, a person taking 1.0 standardized antidepressant drug 
unit would have taken the minimum recommended effective daily dose for one agent. The 
standardized dose was summated for all antidepressants, regardless of class, taken daily. Finally, 
to examine the impact of duration, long-term use was operationally defined as ≥ 2 years and 
short-term use as < 2 years.
13
 
4.2.5 Control variables 
To address potential confounding, we controlled for a number of demographic, health 
status/behavior, and access to care factors.
12,13
 Demographic factors included age, sex, race, site, 
education (less than a high school education, high school graduate, and post-secondary 
education), and marital status (never married, married, previously married). 
Health behavior factors included smoking status and alcohol use. Health status factors 
included pulmonary disease, arthritis, urinary problems, cerebrovascular disease, peripheral 
artery disease, benign prostatic hyperplasia, coronary heart disease, congestive heart disease, 
diabetes, vision (excellent/good sight, fair sight, and poor to completely blind), body mass index 
(underweight/normal, <24.9; overweight, 25.0-29.9; and obese, ≥30), self-reported hypertension, 
and cognitive impairment (The Modified Mini-Mental State Test [3MS] <80).
24
 Self-rated global 
health was dichotomized as excellent/very good/good vs. fair/poor.  
To control for potential confounding by indication we created a time-varying 
dichotomous variable for depressive symptoms (Short Center for Epidemiologic Studies-
Depression [CES-D] Scale >10).
23
 We also included a self-reported variable for history of 
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depression, bodily pain in the past 30 days, sleep problems, anxiety symptoms, and exposure to 
any drug that increases the risk of falls (central nervous system medications, including 
benzodiazepines, antipsychotics, and opioids).
13,23,24
 A continuous time-varying variable was 
created for the total number of prescription medications (excluding dugs that increase falls, and 
antidepressant drugs) per participant. Access to care factors included dichotomous variables for 
hospitalization in previous 12 months, private physician, prescription insurance, and flu shot in 
previous 12 months.
25
 
4.2.6 Statistical Analysis 
We used appropriate descriptive statistics for summarization and generalized estimating 
equations (GEE) for eliciting the main findings.
26-28
 First, we assessed the unadjusted association 
between antidepressant use and recurrent falls over time. Second, a priori covariates that may 
affect recurrent falls were included: site, depressive symptoms, self-reported depression, non-
antidepressant drugs that increase the risk of falls, bodily pain, sleep problems, and anxiety 
symptoms. Each antidepressant sub-class was run as a separate model and controlled for 
antidepressant sub-class use other than the sub-class being evaluated. Finally, additional 
covariates were selected using a forward stepwise selection approach applied separately for each 
of three domains of covariates (demographic, health status/behavior, and access to health care). 
Specifically, stepwise detected covariates and those deemed important a priori were included in 
the final GEE model.  
To address potential confounding, we ran sensitivity analyses. First, we ran bivariate and 
multivariable analyses stratified by presence of a history of falls and/or fracture (after age 45) at 
baseline. Then, we modified our measure of depressive symptoms (CES-D) by isolating those 
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items assessing somatic and non-somatic depressive symptoms.
48
 We then ran bivariate and 
multivariable analyses stratified by presence of depressive symptoms using the original measure 
(including both somatic and non-somatic depressive symptoms; CES-D >10) and the modified 
measure (including only non-somatic depressive symptoms; CES-D >5). All analyses were 
conducted using SAS
®
 software (version 9.3; SAS Institute, Cary, NC) with GENMOD 
procedure to obtain main results. 
4.3 RESULTS 
At baseline, the mean (standard deviation) age was 73.6 (2.9) years, 51.6% were female, 
and 40.8% were black (Table 9). In addition, 5.7% had evidence of serious depressive 
symptoms, and 37.0% had a history of falls/fractures. Baseline characteristics of antidepressant 
users versus nonusers are shown in Table 1. The groups were found to have several differences. 
For example, antidepressant users were more likely to have urinary problems, sleep problems, 
anxiety symptoms, and a hospitalization in the previous 12 months. Moreover, raw scores for the 
CES-D items assessing non-somatic depressive symptoms at baseline are presented in Table 10, 
and the prevalence of depressive symptoms per the CES-D with and without items assessing 
somatic symptoms over time are presented in Table 11. 
Table 12 shows the prevalence of antidepressant use over time. At year 1, 5.8% reported 
antidepressant use. The most common class used was SSRIs, 55.3% were short-term users, and 
57.1% of users took 1-2 SDDs. By year 6, the prevalence of antidepressant use increased to 
9.8%, with SSRIs remaining the most common category used (6.6%). The mean (standard 
deviation) SDDs for each of the three sub-classes are as follows: SSRI, 1.74 (0.94); TCA, 3.45 
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(2.63); and Other, 2.49 (1.98) (data not shown). Moreover, at year 2, 8% of participants reported 
having ≥ 2 falls in the previous year. This rate remained somewhat stable over the next four 
waves (7.5 to 10.4%). 
Table 13 shows the results of the multivariable GEE analyses, controlling for 
demographic, health status/behavior (including depressive symptoms and self-reported 
depression), and access to care factors. Adjusted modeling found a statistically significant 
increase in risk of recurrent falls in antidepressant users (adjusted odds ratio=AOR=1.48; 95% 
confidence interval=CI=1.12-1.96). We also found an increase in risk among those taking SSRIs 
(AOR=1.62, 95% CI=1.15-2.28), those with short duration of use (AOR=1.47, 95% CI=1.04-
2.00), and those taking 1-2 SDD (AOR=1.59, 95% CI=1.15-2.18).  
Regarding sensitivity analyses, among those with a history of falls/fracture at baseline, 
we found an increase in risk for any antidepressant use (AOR=1.83, 95% CI=1.28-2.63), but no 
increased risk was found in those without a history of falls/fracture (Table 14). The stratified 
analysis across years by somatic and non-somatic depressive symptoms revealed similar point 
estimates as the main analysis (CES-D <10, AOR=1.51, 95% CI=1.09-2.10; CES-D >10, 
AOR=1.39, 95% CI=0.83-2.30) (Table 15). Repeating the same analysis but only assessing non-
somatic depressive symptoms showed similar results (CES-D <5, AOR=1.54, 95% CI=1.11-
2.13; CES-D >5, AOR=1.47, 95% CI=0.90-2.39) (Table 16). 
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4.4 DISCUSSION 
This study presents some of the first data to longitudinally assess the association between 
antidepressant use – measured via detailed dosage and duration data – and recurrent falls in 
community-dwelling older adults. Consistent with prior literature, we found a statistically 
significant association between any antidepressant use and recurrent falls after adjusting for 
important potential confounders.
45,46,49
 For example, Kerse et al found that antidepressant use 
was significantly associated with multiple falls and injury but not having sustained a single fall 
(OR 1.46, 95% CI 1.25-1.70).
45
 Moreover, a previous study by Ensrud et al of community-
dwelling older women found that antidepressant use overall was associated with a 54% increased 
risk of frequent falling.
50
 However, unlike our findings, they found the risk of falling among 
antidepressant users to be similar in women with and without a fall in the previous year.
50
  We 
found an increased risk for recurrent falls among those using moderate doses, short duration, and 
in those with a history of falls/fracture. This latter finding highlights the importance of 
measuring and improving drug-disease interactions in older adults.
43
 
Previous investigations over the past several years have reported a significant association 
between users of specific classes of antidepressants and falls in older adults. For example, Quach 
et al found a statistically significant association between SSRIs and outdoor falls in community-
dwelling elders.
46
 Similar to our findings, TCAs and other types of antidepressants were not 
found to be associated with falls, which the authors attributed to the small number of users with 
insufficient statistical power.
46
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Any study of antidepressant use risk must address the role of depressive symptoms. This 
is particularly important because meta-analyses are consistent in that the presence of depressive 
symptoms increases the risk of falling by a factor of almost 1.5.
47
 We paid special attention to 
this potential bias in the current analyses. Ensrud et al stratified analyses by the presence or 
absence of depressive symptoms and found the risk of falls in antidepressant users was similar in 
women with and without depressive symptoms.
50
Our sensitivity analysis revealed similar results 
to the main findings. 
There are important potential limitations to consider for this study. First, the main 
outcome of recurrent falls was retrospectively collected via self-report. However, it is a highly 
specific method in comparison to self-reporting of falls via diary.
21
 Second, medication data 
were collected at fixed annual assessments, preventing us from documenting the exact date in 
which antidepressants were initiated, changed, or discontinued. Third, while it is possible that 
there is residual confounding, we adjusted for common indications for antidepressant therapy. 
Finally, our analysis focused on older, well-functioning community-dwelling Black and White 
men and women from the Memphis and Pittsburgh areas, and the generalizability to older adults 
in other regions or different care settings is unknown.  
In conclusion, antidepressant use overall, SSRI use, short duration of use, and moderate 
dosage were associated with recurrent falls after adjusting for important confounders. Moreover, 
those with a history of falls/fracture had an even greater risk for recurrent falls. 
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Table 10. Characteristics of the Sample at Baseline - Antidepressants (n=2948) 
Variables Overall  
mean + SD or N 
(%) 
 
Antidepressant 
use, 
mean + SD or 
N (%) 
(n=170) 
No antidepressant 
use, 
mean + SD or N 
(%) 
(n=2778) 
P value 
Demographics     
Female gender 1522 (51.6) 107 (62.9) 1415 (50.9) 0.002 
Black race 1203 (40.8) 41 (24.1) 1162 (41.8) <0.001 
Pittsburgh site 1466 (49.7) 77 (45.3) 1389 (50.0) 0.23 
Age 73.6 (2.9) 73.4 (2.70) 73.6 (2.88) 0.37 
Education 
Post secondary 
High school graduate 
< High school 
 
1260 (42.7) 
954 (32.4) 
727 (24.7) 
 
87 (51.2) 
49 (28.8) 
33 (19.4) 
 
1173 (42.2) 
905 (32.6) 
694 (25.0) 
 
0.08 
Married 1531 (52.0) 96 (56.5) 1435 (51.7) 0.36 
Health Behaviors     
Current smoker 302 (10.2) 20 (11.8) 282 (10.2) 0.75 
Alcohol use (≥1 drink per 
week) 
847 (28.7) 41 (24.1) 806 (29.0) 0.37 
Health Status     
Pulmonary disease 298 (10.1) 18 (10.6) 280 (10.1) 0.83 
Arthritis 1650 (56.0) 106 (62.4) 1544 (55.6) 0.22 
Urinary problems 495 (16.8) 40 (23.5) 455 (16.4) 0.02 
Cerebrovascular disease 231 (7.8) 18 (10.6) 213 (7.7) 0.17 
Peripheral arterial disease 149 (5.1) 6 (3.5) 143 (5.2) 0.64 
Benign Prostatic 
Hyperplasia 
692 (23.5) 36 (21.2) 656 (23.6) 0.47 
Coronary heart disease 631 (21.4) 35 (20.6) 596 (21.5) 0.20 
Congestive heart disease 85 (2.9) 6 (3.5) 79 (2.8) 0.55 
Diabetes 440 (14.9) 21 (12.4) 419 (15.1) 0.57 
Vision problems 
Excellent/Good sight 
Fair sight 
Poor to completely blind 
 
2346 (79.6) 
519 (17.6) 
81 (2.8) 
 
136 (80.0) 
30 (17.7) 
4 (2.4) 
 
2210 (79.6) 
489 (17.6) 
77 (2.8) 
 
0.97 
Body Mass Index 
Underweight/Normal 
(<24.9) 
Overweight (25.0-29.9) 
Obese (30+) 
 
947 (32.2) 
 
1257 (42.6) 
744 (25.2) 
 
61 (35.9) 
 
63 (37.1) 
46 (27.1) 
 
886 (31.9) 
 
1194 (43.0) 
698 (25.1) 
 
0.31 
 
Excellent/Very good/Good 
self-rated health 
2479 (84.1) 134 (78.8) 2345 (84.4) 0.12 
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Self-reported hypertension
*
 
Controlled 
Uncontrolled 
 
 
775 (26.3) 
723 (24.5) 
 
 
48 (28.2) 
36 (21.2) 
 
 
727 (26.2) 
687 (24.7) 
 
 
0.56 
Cognitive impairment 
(3MS<80)
*
 
284 (9.6) 13 (7.7) 271 (9.8) 0.45 
Drugs that increase risk of 
falls
*
 
(benzodiazepines, 
antipsychotics, opioids) 
248 (8.4) 
 
49 (28.8) 199 (7.2) <0.001 
No. prescription 
medications
*,†
  
1.8 (2.0) 2.33 (2.13) 1.76 (1.99) <0.001 
Health Status [conditions for which antidepressants are prescribed] 
Self-reported depression  277 (9.4) 88 (51.8) 189 (6.8) <0.001 
Depressive symptoms 
(Short CES-D>10)
*
 
168 (5.7) 
 
27 (15.9) 141 (5.1) <0.001 
Bodily pain (any in past 30 
days) 
1942 (65.9) 120 (70.6) 1822 (65.6) 0.38 
Sleep problems 691 (23.4) 111 (65.3) 1579 (56.8) 0.03 
Anxiety symptoms 414 (14.0) 47 (27.7) 367 (13.2) <0.001 
Access to Care 
Hospitalization in previous 
12 months 
435 (14.8) 35 (20.6) 400 (14.4) 0.03 
Private physician 2319 (78.7) 139 (81.8) 2180 (78.5) 0.31 
Prescription insurance 1861 (63.1) 116 (68.2) 1745 (62.8) 0.16 
Flu shot in previous 12 
months 
2039 (69.2) 124 (72.9) 1915 (68.9) 0.27 
*Time-varying 
†Excluding drugs that increase risk of falls and antidepressants 
Abbreviations: 3MS = Modified Mini-Mental Status Exam; CES-D = Center for Epidemiologic Studies Depression 
Scale; CNS= central nervous system; SD= standard deviation 
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Table 11. CES-D Items Assessing Non-somatic Symptoms at Baseline (n=2948) 
CES-D Item N N 
missing 
Mean Median SD Min. Max. 
I was depressed.  2925 23 0.189 0 0.505 0 3 
I felt hopeful about the 
future. 
2872 76 0.569 0 0.922 0 3 
I felt fearful.  2923 25 0.104 0 0.369 0 3 
I was happy.  2893 55 0.422 0 0.760 0 3 
I felt lonely.  2929 19 0.237 0 0.566 0 3 
Overall 2939 9 1.488 1.00 2.009 0 15.00 
Abbreviations: CES-D = Center for Epidemiologic Studies Depression Scale; max: maximum; min: minimum; SD: 
standard deviation 
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Table 12. Prevalence of Depressive Symptoms per the CES-D with and without Items Assessing 
Somatic Symptoms Over Time 
 Year 1 
(n=2948) 
n, % 
Year 2 
(n=2811) 
n, % 
Year 3 
(n=2679) 
n, % 
Year 5 
(n=2489) 
n, % 
Year 6 
(n=2388) 
n, % 
CES-D > 10 
(including 
items assessing 
somatic 
symptoms) 
168 (5.7) -- 321 (12.0) 336 (13.5) 329 (13.8) 
CES-D > 5 
(not including 
items assessing 
somatic 
symptoms) 
250 (8.5) -- 501 (18.7) 475 (19.1) 417 (17.5) 
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Table 13. Antidepressant Use over Time* 
Antidepressant 
Medication Use 
Year 1 
(n=2948) 
n, % 
Year 2 
(n=2811) 
n, % 
Year 3 
(n=2679) 
n, % 
Year 5 
(n=2489) 
n, % 
Year 6 
(n=2388) 
n, % 
Any Use 170 (5.8) 189 (6.7) 219 (8.2) 220 (8.8) 235 (9.8) 
SDD ≥2 67 (2.3) 78 (2.8) 75 (2.8) 74 (3.0) 88 (3.7) 
SDD 1-2 97 (3.3) 120 (4.3) 156 (5.8) 176 (7.1) 189 (7.9) 
SDD <1 11 (0.4) 19 (0.7) 26 (1.0) 22 (0.9) 27 (1.1) 
Long Term use (≥2 years) 74 (2.5) 100 (3.6) 104 (3.9) 119 (4.8) 122 (5.1) 
Short Term Use 94 (3.2) 98 (3.5) 129 (4.8) 117 (4.7) 144 (6.0) 
Specific Class Use 
SSRI 
TCA 
Others
†
 
-- 
73 (2.5) 
70 (2.4) 
31 (1.1) 
-- 
90 (3.2) 
71 (2.5) 
41 (1.5) 
-- 
123 (4.6) 
59 (2.2) 
51 (1.9) 
-- 
139 (5.6) 
44 (1.8) 
49 (2.0) 
-- 
158 (6.6) 
44 (1.8) 
44 (1.8)  
*Medication data not available at year 4 
†Others: trazodone, bupropion, venlafaxine, mirtazapine, phenelzine 
Abbreviations: SDD: standardized daily dose; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic 
antidepressant 
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Table 14. Association between Antidepressant Use and Recurrent Falls, with and without Controlling 
for Covariates (Including Depressive Symptoms) 
Antidepressant Medication Use
*
 Bivariate OR (95% CI) Adjusted OR (95% CI)
†
 
Any Use 1.99 (1.60-2.48) 1.48 (1.12-1.96) 
Long duration (≥2 years) 1.77 (1.31-2.40) 1.31 (0.88-1.95) 
Short duration 1.79 (1.36-2.36) 1.47 (1.04-2.00) 
SDD – ≥2 1.35 (0.90-2.02) 1.03 (0.64-1.65) 
SDD – 1-2 1.91 (1.47-2.49) 1.59 (1.15-2.18) 
SDD – <1 1.57 (0.81-3.04) 1.18 (0.49-2.87) 
Specific Class Use
§
 -- -- 
SSRI 2.23 (1.68-2.97) 1.62 (1.15-2.28) 
TCA 1.61 (1.08-2.40) 1.27 (0.76-2.13) 
Others
‡
 1.79 (1.07-3.00) 1.34 (0.72-2.50) 
Abbreviations: OR=odds ratio; CI=confidence interval; SDD: standardized daily dose; SSRI: selective serotonin 
reuptake inhibitor; TCA: tricyclic antidepressant 
*Reference group is No Use 
†Controlling for variables forced into the model (i.e., site, drugs that increase the risk of falls, self-reported 
depression, depressive symptoms per CES-D 10, bodily pain, sleep problems, and anxiety symptoms) and those 
from forward selection procedures (i.e.,  
age, pulmonary disease, arthritis, urinary problems, cerebrovascular disease, diabetes, 
vision problems, hospitalization in previous 12 months, and private physician) 
‡Others: trazodone, bupropion, venlafaxine, mirtazapine, phenelzine 
§Each antidepressant sub-class was run as a separate model and controlled for antidepressant sub-class use other 
than the sub-class being evaluated 
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Table 15. Bivariate and Multivariable Association between Antidepressant Use and Recurrent Falls 
Stratified by History of Falls and/or Fracture (after age 45) at Baseline 
 History of Falls/Fracture 
(n=1092) 
 
No History of Falls/Fracture 
(n=1856) 
 
Antidepressant 
Medication Use
*
 
Crude OR (95% CI) Adj. OR (95% CI)
†
 Crude OR (95% CI) Adj. OR (95% CI)
†
 
Any use 2.02 (1.51-2.69) 1.83 (1.28-2.63) 1.83 (1.30-2.59) 0.97 (0.60-1.56) 
Long duration (≥2 years) 1.61 (1.09-2.39) 1.38 (0.82-2.30) 1.84 (1.15-2.95) 1.30 (0.69-2.42) 
Short duration 1.85 (1.30-2.64) 1.77 (1.17-2.68) 1.61 (1.03-2.51) 0.79 (0.42-1.48) 
SDD ≥2 1.39 (0.81-2.40) 1.06 (0.57-1.97) 1.13 (0.63-2.06) 0.98 (0.48-2.01) 
SDD 1-2 1.80 (1.26-2.57) 1.99 (1.31-3.01) 1.97 (1.34-2.88) 1.17 (0.71-1.93) 
SDD <1 1.16 (0.41-3.31) 0.75 (0.18-3.05) 2.22 (0.99-4.93) 1.89 (0.67-5.36) 
Specific Class Use
§
 -- -- -- -- 
SSRI 2.12 (1.49-3.02) 1.92 (1.24-2.97) 2.21 (1.40-3.48) 1.11 (0.62-2.01) 
TCA 1.86 (1.11-3.09) 1.47 (0.77-2.82) 1.25 (0.64-2.41) 0.86 (0.35-2.13) 
Others‡ 1.90 (0.90-4.01) 2.22 (0.99-4.94) 1.65 (0.80-3.40) 0.76 (0.27-2.12) 
Abbreviations: OR: odds ratio; CI=confidence interval; SDD: standardized daily dose; SSRI: selective serotonin 
reuptake inhibitor; TCA: tricyclic antidepressant 
*Reference group is No Use  
†Controlling for variables forced into the model (i.e., site, drugs that increase the risk of falls, self-reported 
depression, depressive symptoms per CES-D 10, bodily pain, sleep problems, and anxiety symptoms) and those 
from forward selection procedures (i.e., age, pulmonary disease, arthritis, urinary problems, cerebrovascular disease, 
diabetes, vision problems, hospitalization in previous 12 months, and private physician) 
‡Others: trazodone, bupropion, venlafaxine, mirtazapine, phenelzine 
§Each antidepressant sub-class was run as a separate model and controlled for antidepressant sub-class use other 
than the sub-class being evaluated 
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Table 16. Bivariate and Multivariable Association between Antidepressant Use and Recurrent Falls 
Stratified by Time-Varying Depressive Symptoms per CES-D 10 
 CES-D > 10 
 
CES-D < 10 
 
Antidepressant 
Medication Use
*
 
Crude OR (95% CI) Adj. OR (95% CI)
 †
 Crude OR (95% CI) Adj. OR (95% CI)
 †
 
Any use 1.88 (1.27-2.80) 1.39 (0.83-2.30) 1.88 (1.43-2.47) 1.51 (1.09-2.10) 
Long duration (≥2 
years) 
1.67 (0.92-3.02) 1.31 (0.66-2.61) 1.99 (1.37-2.88) 1.43 (0.92-2.23) 
Short duration 1.74 (1.11-2.72) 1.42 (0.79-2.54) 1.52 (1.06-2.18) 1.47 (0.99-2.19) 
SDD ≥2 1.32 (0.61-2.83) 1.12 (0.53-2.40) 1.13 (0.64-2.00) 0.99 (0.54-1.85) 
SDD 1-2 1.88 (1.18-2.99) 1.69 (0.97-2.94) 1.79 (1.28-2.50) 1.56 (1.07-2.29) 
SDD <1 0.83 (0.23-2.93) 0.50 (0.08-3.12) 2.20 (1.02-4.76) 1.68 (0.66-4.31) 
Abbreviations: CES-D = Center for Epidemiologic Studies Depression Scale; CI=confidence interval; OR: odds 
ratio; SDD: standardized daily dose; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant 
*Reference group is No Use  
†Controlling for variables forced into the model (i.e., site, drugs that increase the risk of falls, self-reported 
depression, bodily pain, sleep problems, and anxiety symptoms) and those from forward selection procedures (i.e., 
age, pulmonary disease, arthritis, urinary problems, cerebrovascular disease, diabetes, vision problems, 
hospitalization in previous 12 months, and private physician) 
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Table 17. Bivariate and Multivariable Association between Antidepressant Use and Recurrent Falls 
Stratified by Time-Varying Depressive Symptoms per CES-D with Items Assessing Non-somatic Symptoms 
 CES-D > 5 
 
CES-D < 5 
 
Antidepressant 
Medication Use
*
 
Crude OR (95% CI) Adj. OR (95% CI)
 †
 Crude OR (95% CI) Adj. OR (95% CI)
 †
 
Any use 2.18 (1.49-3.18) 1.47 (0.90-2.39) 1.91 (1.45-2.53) 1.54 (1.11-2.13) 
Long duration (≥2 
years) 
2.04 (1.21-3.45) 1.42 (0.74-2.72) 2.00 (1.38-2.90) 1.53 (0.98-2.37) 
Short duration 1.92 (1.24-2.96) 1.52 (0.87-2.63) 1.50 (1.02-2.20) 1.37 (0.89-2.11) 
SDD ≥2 1.36 (0.65-2.87) 0.97 (0.45-2.08) 1.19 (0.70-2.03) 1.11 (0.62-1.97) 
SDD 1-2 2.20 (1.43-3.40) 1.95 (1.17-3.27) 1.78 (1.26-2.53) 1.53 (1.02-2.27) 
SDD <1 0.87 (0.29-2.68) 0.31 (0.06-1.74) 2.42 (1.12-5.23) 2.14 (0.87-5.22) 
Abbreviations: CES-D = Center for Epidemiologic Studies Depression Scale; CI=confidence interval; OR: odds 
ratio; SDD: standardized daily dose; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant 
*Reference group is No Use  
†Controlling for variables forced into the model (i.e., site, drugs that increase the risk of falls, self-reported 
depression, bodily pain, sleep problems, and anxiety symptoms) and those from forward selection procedures (i.e., 
age, pulmonary disease, arthritis, urinary problems, cerebrovascular disease, diabetes, 
vision problems, hospitalization in previous 12 months, and private physician) 
 65 
5.0  DISCUSSION 
I believe the findings from this dissertation contribute to a better understanding of 
recurrent medication-related falls in community-dwelling older adults. First, we found that 
antihypertensive use overall was not associated with recurrent falls after adjusting for important 
confounders. However, we reported that loop diuretic use may be associated with recurrent falls, 
and this finding needs further study. Second, while increased point estimates suggested an 
association of anticholinergic use with recurrent falls, none of them reached statistical 
significance. This finding is consistent with prior literature showing no significant association 
between anticholinergic use and recurrent falls in community-dwelling elders. Third, we were 
able to replicate prior studies’ findings showing a statistically significant association between 
antidepressant use and recurrent falls. Importantly, we found an even greater risk among those 
with a history of a fall or fracture, suggesting that this could be a high-risk group to target future 
interventions. In addition, SSRI use, short duration of use, and moderate dosage were associated 
with recurrent falls after adjusting for important confounders. Moreover, sensitivity analyses 
using a sample stratified by a time-varying measure of depressive symptoms found an increased 
risk of recurrent falls. 
There are several strengths of these three analyses. First, all study designs were 
longitudinal, which allowed for a more robust assessment of risk over time compared to a cross-
sectional analysis. Second, we used state-of-the-art methods to calculate medication dosage 
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variables, filling a gap in the previous literature. Third, we assessed various sub-class analyses to 
examine drug risk at a more granular level. Finally, we used sophisticated statistical methods to 
account for the longitudinal nature of the study and conducted multiple sensitivity analyses to 
assess the robustness of our findings. There are, of course, important limitations to this work as 
well, which have been previously described within the individual manuscripts. 
Looking forward, important questions remain. First, very little is known about shared risk 
factors between falls and fractures in older adults. Are certain medications associated with only 
falls, only fractures, or both? In addition, very little is understood about medication-related 
mechanisms to cause falls in older adults. Moreover, many new antidepressants have reached the 
market in the past few years, and it is not clear which individual agent(s) (as opposed to sub-
class) is/are the safest for older adults to take in terms of falls risk. Additional comparative 
effectiveness research is needed using more recent data and including these newer agents. 
Finally, there is a great need for feasible and scalable interventions to reduce medication-related 
falls in community-dwelling older adults. Unfortunately, there is no clear evidence currently 
available for an effective intervention to be widely implemented.
51
 Health information 
technologies are a promising approach to reducing the risk of falls in older adults through alerts 
for risky medications.
51
 Until more effective interventions are available, the following quote 
from a thought leader in the field summarizes a practical approach to reducing medication-
related falls risk: “By eliminating unnecessary medications and reducing the dose of necessary 
medications, it is often possible to treat coexisting conditions while minimizing risk of 
medication-related fall or injury.”3 
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